This work highlights the importance of interleukin-1 in human preterm labor, as well as efforts to identify safe and potent IL-1-targeting agents and diagnostics with high negative and positive predictive value to respectively treat and identify women at risk of preterm deliveries.
Tandem use of new diagnostics and therapies will incentivise development of effective clinical modalities to tackle this unmet medical need.